Reply to "Challenges to the Long-Term Safety Claims of Extremely Low-Dose Amiodarone: Pulmonary, Thyroid, Hepatic, and Statistical Concerns".
作者信息
Yoshida Kentaro
机构信息
Department of Cardiology Institute of Medicine, University of Tsukuba Tsukuba Japan.
Department of Cardiology Ibaraki Prefectural Central Hospital Kasama Japan.
出版信息
J Arrhythm. 2025 Sep 12;41(5):e70194. doi: 10.1002/joa3.70194. eCollection 2025 Oct.
Abstract
摘要
相似文献
1
Reply to "Challenges to the Long-Term Safety Claims of Extremely Low-Dose Amiodarone: Pulmonary, Thyroid, Hepatic, and Statistical Concerns".对《极低剂量胺碘酮长期安全性声明面临的挑战：肺部、甲状腺、肝脏及统计学方面的担忧》的回复
J Arrhythm. 2025 Sep 12;41(5):e70194. doi: 10.1002/joa3.70194. eCollection 2025 Oct.
2
Challenges to the Long-Term Safety Claims of Extremely Low-Dose Amiodarone: Pulmonary, Thyroid, Hepatic, and Statistical Concerns.极低剂量胺碘酮长期安全性声明面临的挑战：肺部、甲状腺、肝脏及统计学方面的问题。
J Arrhythm. 2025 Aug 20;41(4):e70174. doi: 10.1002/joa3.70174. eCollection 2025 Aug.
3
Long-Term Safety of Extremely Low-Dose Amiodarone at 50 mg Daily in Patients With Persistent Atrial Fibrillation.每日50毫克极低剂量胺碘酮治疗持续性心房颤动患者的长期安全性
J Arrhythm. 2025 Jul 17;41(4):e70150. doi: 10.1002/joa3.70150. eCollection 2025 Aug.
4
Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death.胺碘酮与其他预防心源性猝死的药物干预措施的比较
Cochrane Database Syst Rev. 2015 Dec 8;2015(12):CD008093. doi: 10.1002/14651858.CD008093.pub2.
5
Effectiveness of Pharmacist-Led Amiodarone Monitoring Services on Improving Adherence to Amiodarone Monitoring Recommendations: A Systematic Review.药师主导的胺碘酮监测服务对提高胺碘酮监测建议依从性的有效性：一项系统评价。
Pharmacotherapy. 2016 Feb;36(2):230-6. doi: 10.1002/phar.1697. Epub 2016 Feb 5.
6
Amiodarone induced thyroid dysfunction: A high cumulative incidence in a nationwide cohort study in Iceland.胺碘酮诱发的甲状腺功能障碍：冰岛一项全国性队列研究中的高累积发病率。
J Intern Med. 2025 Sep;298(3):228-236. doi: 10.1111/joim.20115. Epub 2025 Jul 10.
7
Acute amiodarone-induced pulmonary toxicity in adult ICU patients with new-onset atrial fibrillation-A systematic review.成人 ICU 新发心房颤动患者中急性胺碘酮诱导的肺毒性：系统评价。
Acta Anaesthesiol Scand. 2025 Jan;69(1):e14535. doi: 10.1111/aas.14535. Epub 2024 Oct 17.
8
Association between amiodarone and thyrotoxicosis in patients with atrial fibrillation and hypothyroidism.胺碘酮与心房颤动合并甲状腺功能减退患者甲状腺毒症之间的关联。
Heart Rhythm. 2025 Aug 5. doi: 10.1016/j.hrthm.2025.08.003.
9
Environmental Iodine Content, Female Sex and Age Are Associated with New-Onset Amiodarone-Induced Hypothyroidism: A Systematic Review and Meta-Analysis of Adverse Reactions of Amiodarone on the Thyroid.环境碘含量、女性性别和年龄与胺碘酮所致新发甲状腺功能减退有关：胺碘酮对甲状腺不良反应的系统评价和荟萃分析
Cardiology. 2016;134(3):366-71. doi: 10.1159/000444578. Epub 2016 Apr 22.
10
The Therapeutic Potential of Propranolol and Other Beta-Blockers in Hyperthyroidism.普萘洛尔及其他β受体阻滞剂在甲状腺功能亢进症中的治疗潜力
Int J Mol Sci. 2025 Aug 27;26(17):8322. doi: 10.3390/ijms26178322.
本文引用的文献
1
Challenges to the Long-Term Safety Claims of Extremely Low-Dose Amiodarone: Pulmonary, Thyroid, Hepatic, and Statistical Concerns.极低剂量胺碘酮长期安全性声明面临的挑战：肺部、甲状腺、肝脏及统计学方面的问题。
J Arrhythm. 2025 Aug 20;41(4):e70174. doi: 10.1002/joa3.70174. eCollection 2025 Aug.
2
Long-Term Safety of Extremely Low-Dose Amiodarone at 50 mg Daily in Patients With Persistent Atrial Fibrillation.每日50毫克极低剂量胺碘酮治疗持续性心房颤动患者的长期安全性
J Arrhythm. 2025 Jul 17;41(4):e70150. doi: 10.1002/joa3.70150. eCollection 2025 Aug.
Zotero 插件